Scarica l'app Stockscreener
1.965
1.28%
0.005
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome
Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - Vinanet
Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
CRDL Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - Vinanet
Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca
Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat
Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca
Cardiol Therapeutics (CRDL) Gains 1.76% to $1.45, Holding Above Key SupportBPI Bull Correction - Vinanet
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday - MarketBeat
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics to Present Heart Disease Pipeline at Canaccord Genuity Growth Conference - TipRanks
Cardiol Therapeutics Inc. (NASDAQ: CRDL) at Canaccord 46th Growth Conference - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference - The Globe and Mail
Cardiol Therapeutics to Join Boston Chat on Heart Disease Therapies - Stock Titan
Cardiol Therapeutics (CRDL) Holds Steady at $1.30 as Shares Consolidate Between Support and ResistanceRegression Channel - dars.gov.et
Cardiol's Pivotal Phase III Heart Trial Reaches 75% Enrolment as Leading U.S. Medical Centres Join the Race - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
CRDL|Cardiol Therapeutics Inc|Price:1.300|Chg%:+0.030 - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Shares Decline as Biotech Risk, Clinical Uncertainty and Investor Caution Pressure Outlook - kalkine.ca
HC Wainwright Analysts Decrease Earnings Estimates for CRDL - MarketBeat
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.330|Chg%:+0.020 - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
CRDL Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pre-Revenue R&D ProgressSpecial Dividend Alert - Vinanet
Cardiol Therapeutics (CRDL) Gains 4.13% as Bullish Momentum Builds Above $1.23 SupportDouble EMA - dars.gov.et
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
CRDL Stock Price, Quote & Chart - ChartMill
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today - Wealth Awesome
Cardiol Therapeutics (TSX:CRDL) Expands Visibility Across Healthcare Sector - Kalkine Media
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data - t.co
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
2.13%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):